-
Indivior Inc. et al v. Teva Pharmaceuticals USA, Inc. DC CAFC
- 1:16-cv-00178
- D. Del.
- Judge: Richard G. Andrews
- Filed: 03/21/2016
- Closed: 09/05/2019
- Latest Docket Entry: 09/05/2019
- PACER
- Docket updated daily
3
Plaintiffs
1
Defendant
1
Accused
Product
5
Patents-in-Suit
1,264
Days in
Litigation
-
Indivior Inc. et al v. Teva Pharmaceuticals USA, Inc. DC CAFC
- 1:16-cv-00178
- D. Del.
- Judge: Richard G. Andrews
- Filed: 03/21/2016
- Closed: 09/05/2019
- Latest Docket Entry: 09/05/2019
- PACER
- Docket updated daily
Causes of Action
Infringement
Declaratory Judgment
Patent Infringement
Market Sector
Biotech and Pharma
Court
Assigned Judge
Outcome Summary
- Patent Information
-
Validity & Enforceability
Claim # | Claim Text | Outcome |
---|---|---|
1 |
A mucosally-adhesive water-soluble film product comprising: an analgesic opiate pharmaceutical active; and at least one water-soluble polymer component consisting of polyethylene oxide in combination with a hydrophilic cellulosic polymer; wherein:
view more
|
Valid
Entry 20 |
4 |
The film product according to claim 1, further comprising an additional pharmaceutical active.
|
Valid
Entry 20 |
5 |
The film product according to claim 1, further comprising one or more sweeteners.
|
Valid
Entry 20 |
8 |
The film product according to claim 1, further comprising one or more flavors.
|
Valid
Entry 20 |
9 |
The film product according to claim 1, further comprising one or more buffers.
|
Valid
Entry 20 |
Claim # | Claim Text | Outcome |
---|---|---|
62 |
A drug delivery composition comprising: (i) a cast film comprising a flowable water-soluble or water swellable film-forming matrix comprising one or more substantially water soluble or water swellable polymers; and a desired amount of at least one
view more
|
Valid
Entry 20 |
63 |
The drug delivery composition of claim 62, wherein the particulate active has a particle size of 150 microns or less.
|
Valid
Entry 20 |
64 |
The drug delivery composition of claim 62, wherein the particulate active has a particle size of 100 microns or less.
|
Valid
Entry 20 |
65 |
The drug delivery composition of claim 62, wherein said variation of drug content is less than 5% by weight per film dosage unit.
|
Valid
Entry 20 |
71 |
The drug delivery composition of claim 62, wherein said active is selected from the group consisting of antimicrobial agents, non-steroidal anti-inflammatory drugs, anti-tussives, decongestants, antihistamines, expectorants, anti-diarrheals, H<sub>2
view more
|
Valid
Entry 20 |
73 |
The drug delivery composition of claim 62, wherein said active is an opiate or opiate derivative.
|
Valid
Entry 20 |
Claim # | Claim Text | Outcome |
---|---|---|
24 |
The process of claim 1, wherein said active is in the form of a particle.
|
Valid
Entry 20 |
-
Infringement
Teva Pharmaceuticals USA, Inc.
- 3 Details
Accused Product | Patent # | Claim # | Outcome |
---|---|---|---|
generic version of Plaintiff Indivior’s Suboxone® sublingual film and ANDA | US 8,017,150 B2 |
1, 4, 5, 8, 9
|
No infringement
Entry 20
|
generic version of Plaintiff Indivior’s Suboxone® sublingual film and ANDA | US 8,603,514 B2 |
62, 63, 64, 65, 71, 73
|
No infringement
Entry 20
|
generic version of Plaintiff Indivior’s Suboxone® sublingual film and ANDA | US 8,900,497 B2 |
24
|
No infringement
Entry 20
|